GO:0047887 farnesyl diphosphate kinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0047887 (farnesyl diphosphate kinase activity) catalyzes the phosphorylation of 2-trans,6-trans-farnesyl diphosphate (FPP) to farnesyl triphosphate using ATP.
• This activity is part of the mevalonate pathway and is tightly linked to isoprenoid biosynthesis, including cholesterol and prenyl groups for protein modification.
• Farnesyl diphosphate synthase (FDPS) is a key upstream enzyme that produces FPP, the substrate for this kinase activity.
• Dysregulation of the mevalonate pathway, including FPP metabolism, is implicated in cancers such as hepatocellular carcinoma and in statin-associated neuromyotoxicity.
• Experimental models for studying this activity include CRISPR knockout, point mutation, knock-in, and overexpression of genes such as FDPS, FDFT1, and MVK.
• Targeting FPP metabolism is a therapeutic strategy, with inhibitors of FDPS and related enzymes under investigation.
Description
Farnesyl diphosphate kinase activity (GO:0047887) is a molecular function that catalyzes the transfer of a phosphate group from ATP to 2-trans,6-trans-farnesyl diphosphate (FPP), yielding farnesyl triphosphate and ADP. This reaction sits within the mevalonate pathway, a central metabolic route that produces sterols, dolichols, ubiquinones, and prenylated proteins. The enzyme responsible for this activity has not been extensively characterized in humans, but its substrate, FPP, is a critical branch-point intermediate generated by farnesyl diphosphate synthase (FDPS). Understanding this kinase activity is important because FPP levels influence diverse cellular processes, from cholesterol synthesis to protein prenylation, and perturbations in the mevalonate pathway are linked to cancer, cardiovascular disease, and neuromuscular toxicity. Researchers studying this activity often focus on the enzymes that produce or consume FPP, such as FDPS, farnesyl-diphosphate farnesyltransferase 1 (FDFT1), and mevalonate kinase (MVK). The availability of CRISPR-based tools now enables precise interrogation of these genes in relevant cell models.
farnesyl diphosphate kinase activity At A Glance
| GO ID | GO:0047887 |
|---|---|
| GO term | farnesyl diphosphate kinase activity |
| Ontology | molecular_function |
| Synonym | ATP:farnesyl-diphosphate phosphotransferase activity; farnesyl-diphosphate kinase activity; farnesyl pyrophosphate kinase activity |
| Definition | Catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate + ATP = 2-trans,6-trans-farnesyl triphosphate + ADP. |
| Major function | Phosphorylation of farnesyl diphosphate to farnesyl triphosphate |
| Related pathway | Mevalonate pathway / isoprenoid biosynthesis |
| Substrate | 2-trans,6-trans-farnesyl diphosphate (FPP) |
| Product | 2-trans,6-trans-farnesyl triphosphate |
What Is GO:0047887?
Farnesyl diphosphate kinase activity is defined as the catalysis of the reaction: 2-trans,6-trans-farnesyl diphosphate + ATP = 2-trans,6-trans-farnesyl triphosphate + ADP. In other words, it is an enzymatic activity that adds a terminal phosphate to the farnesyl diphosphate molecule, using ATP as the phosphate donor. This activity is classified as a molecular function (GO:0047887) and is synonymous with ATP:farnesyl-diphosphate phosphotransferase activity, farnesyl-diphosphate kinase activity, and farnesyl pyrophosphate kinase activity.
Why Is farnesyl diphosphate kinase activity Important in Cell Biology?
Farnesyl diphosphate kinase activity is important because it acts on farnesyl diphosphate (FPP), a key intermediate in the mevalonate pathway that is required for the synthesis of cholesterol, bile acids, and prenylated proteins. By converting FPP to farnesyl triphosphate, this activity may regulate the pool of FPP available for other branches of the pathway, including sterol synthesis and protein farnesylation. Dysregulation of FPP metabolism has been implicated in hepatocellular carcinoma progression, where targeting FDFT1 reduces cholesterol and bile acid production and delays tumor growth. Additionally, statins, which inhibit the mevalonate pathway upstream of FPP, can cause neuromyotoxicity, highlighting the clinical importance of this metabolic node. Inhibitors of FPP-consuming enzymes, such as farnesyl pyrophosphate synthase, are being explored as therapeutic agents. Therefore, understanding the regulation and function of farnesyl diphosphate kinase activity could reveal new targets for cancer, cardiovascular, and metabolic diseases.
• Provides a route for farnesyl triphosphate synthesis, a less characterized isoprenoid derivative.
• Regulates the availability of FPP for cholesterol and bile acid biosynthesis.
• Influences protein prenylation, which is critical for Ras and other small GTPase signaling.
• Linked to cancer: FDFT1 targeting reduces HCC progression via HNF4A/ALDOB/AKT1 axis.
• Implicated in statin-associated neuromyotoxicity through mevalonate pathway inhibition.
• Potential therapeutic target in pulmonary arterial hypertension via FDPS regulation.
• Relevant to metabolic disorders involving mevalonate kinase deficiency.
• Enables research on isoprenoid flux and its impact on cell proliferation and autophagy.
• Supports development of enzyme inhibitors that modulate FPP levels.
• Facilitates CRISPR-based functional genomics of mevalonate pathway genes.
Molecular Mechanism of farnesyl diphosphate kinase activity
Substrate recognition and binding
In simple terms: The enzyme grabs farnesyl diphosphate and ATP to start the reaction.
Farnesyl diphosphate kinase activity requires the binding of 2-trans,6-trans-farnesyl diphosphate (FPP) and ATP. FPP is a 15-carbon isoprenoid produced by farnesyl diphosphate synthase (FDPS) in the mevalonate pathway. The kinase likely recognizes the diphosphate moiety of FPP and the adenine ring of ATP, positioning them for phosphoryl transfer. Structural studies of related kinases suggest a conserved ATP-binding fold, but the exact enzyme responsible for this activity in humans remains to be identified.
Catalytic phosphoryl transfer
In simple terms: A phosphate group is moved from ATP onto FPP.
The catalytic step involves the transfer of the gamma-phosphate from ATP to the terminal phosphate of FPP, forming farnesyl triphosphate and ADP. This reaction is analogous to other diphosphate kinases that use ATP as a phosphodonor. The reaction is reversible under certain conditions, but in vivo it likely proceeds toward farnesyl triphosphate formation when ATP is abundant. The enzyme may require divalent metal ions such as Mg2+ for catalysis, as is common for kinases, though direct evidence for this specific activity is limited.
Product release and metabolic fate
In simple terms: The product, farnesyl triphosphate, is released and can be used elsewhere.
After catalysis, farnesyl triphosphate is released. This molecule is a triphosphate ester of farnesol and may serve as a substrate for further reactions or as a signaling molecule. Its role is not well defined, but it could be hydrolyzed by phosphatases to regenerate FPP or farnesol. The balance between FPP and farnesyl triphosphate may influence the flux of isoprenoids toward sterol synthesis or protein prenylation.
Regulation by mevalonate pathway intermediates
In simple terms: The reaction is controlled by how much FPP and ATP are available.
The activity of farnesyl diphosphate kinase is likely regulated by the availability of its substrates, FPP and ATP, which are influenced by upstream enzymes such as FDPS and mevalonate kinase (MVK). Inhibitors of FDPS, such as allosteric inhibitors of farnesyl pyrophosphate synthase, can reduce FPP levels and potentially affect this kinase activity. Additionally, statins inhibit HMG-CoA reductase, decreasing upstream mevalonate and FPP, which may indirectly modulate this activity.
Integration with protein prenylation
In simple terms: FPP is also used to modify proteins, so this kinase competes with that process.
FPP is a substrate for protein farnesyltransferases, which attach a farnesyl group to cysteine residues of proteins such as Ras. By converting FPP to farnesyl triphosphate, farnesyl diphosphate kinase activity may reduce the pool of FPP available for prenylation. This interplay is significant because farnesyltransferase inhibitors were developed as anticancer agents, and modulation of FPP levels could impact their efficacy. Thus, this kinase activity may indirectly influence Ras signaling and other prenylation-dependent pathways.
Key Genes Involved in GO:0047887 farnesyl diphosphate kinase activity
The following genes and proteins are directly or indirectly involved in farnesyl diphosphate metabolism and the mevalonate pathway, and they are commonly studied in the context of GO:0047887.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FDPS | Farnesyl diphosphate synthase; produces FPP | Upstream of GO:0047887; target in pulmonary arterial hypertension |
| FDFT1 | Farnesyl-diphosphate farnesyltransferase 1; converts FPP to squalene | Target in hepatocellular carcinoma; affects cholesterol/bile acid production |
| MVK | Mevalonate kinase; phosphorylates mevalonate in the pathway | Inhibited by allosteric FDPS inhibitors; related to mevalonate kinase deficiency |
| HMGCR | HMG-CoA reductase; rate-limiting enzyme of mevalonate pathway | Target of statins; linked to neuromyotoxicity |
| RAS | Small GTPase; farnesylated for membrane localization | FPP is substrate for Ras farnesyltransferase; inhibitors developed |
| TAZ | Transcriptional coactivator; regulates HCC growth | Drives HCC via ANLN and KIF23; mevalonate pathway crosstalk |
| TEAD2 | Transcription factor; partner of TAZ | Therapeutically targetable in HCC |
| ANLN | Actin-binding protein; involved in cytokinesis | Downstream of TAZ-TEAD2 in HCC |
| KIF23 | Kinesin-like protein; involved in mitosis | Downstream of TAZ-TEAD2 in HCC |
| HNF4A | Hepatocyte nuclear factor 4 alpha | Part of FDFT1/HNF4A/ALDOB/AKT1 axis in HCC |
| ALDOB | Aldolase B; glycolytic enzyme | Part of FDFT1/HNF4A/ALDOB/AKT1 axis in HCC |
| AKT1 | Serine/threonine kinase; survival signaling | Part of FDFT1/HNF4A/ALDOB/AKT1 axis in HCC |
| FDPS (isoform) | Peroxisomal farnesyl diphosphate synthase | Localized in peroxisomes; contributes to isoprenoid synthesis |
| GGPS1 | Geranylgeranyl diphosphate synthase; related prenyltransferase | Produces GGPP for protein geranylgeranylation; competes with FPP |
| SQS | Squalene synthase; converts FPP to squalene | Branch-point enzyme for sterol synthesis |
| CYP51A1 | Lanosterol 14-alpha demethylase; sterol biosynthesis | Downstream of FPP; affected by FDFT1 targeting |
| LSS | Lanosterol synthase; converts squalene to lanosterol | Sterol pathway enzyme; potential model for flux analysis |
| DHCR7 | 7-dehydrocholesterol reductase; cholesterol synthesis | Terminal step of cholesterol synthesis; linked to FPP flux |
How Is farnesyl diphosphate kinase activity Regulated?
The activity of farnesyl diphosphate kinase is regulated primarily by the availability of its substrates, FPP and ATP, which are controlled by the mevalonate pathway. Upstream enzymes such as HMG-CoA reductase, mevalonate kinase, and farnesyl diphosphate synthase (FDPS) determine the flux of carbon into FPP. FDPS is localized in peroxisomes, suggesting compartmentalization of FPP synthesis that may influence access to the kinase. Statins inhibit HMG-CoA reductase, reducing mevalonate and FPP levels, and can cause neuromyotoxicity, indicating that tight regulation of this pathway is critical for normal cell function. Additionally, allosteric inhibitors of FDPS can lower FPP, potentially affecting farnesyl diphosphate kinase activity. Transcriptional regulation of mevalonate pathway genes by SREBP transcription factors also modulates FPP availability, though direct regulation of the kinase itself is not well characterized.
farnesyl diphosphate kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FDFT1 | Hepatocellular carcinoma; cholesterol/bile acid production | CRISPR knockout in HCC cell lines (e.g., HepG2, Huh7) |
| FDPS | Pulmonary arterial hypertension; endothelial proliferation | Knockdown or knockout in rat pulmonary endothelial cells |
| MVK | Mevalonate kinase deficiency; autoinflammation | Point mutation knock-in in HEK293 or patient-derived cells |
| HMGCR | Statin-associated neuromyotoxicity | Overexpression or point mutation in muscle cell lines |
| RAS | Cancer; protein prenylation | Knock-in of farnesylation-deficient Ras mutants in cancer cells |
Hepatocellular carcinoma (HCC)
The mevalonate pathway is increasingly recognized as a driver of HCC. Targeting FDFT1, which converts FPP to squalene, reduces cholesterol and bile acid production and delays HCC progression through the HNF4A/ALDOB/AKT1 axis. This suggests that enzymes consuming FPP, including farnesyl diphosphate kinase, may influence HCC growth by altering FPP flux. Additionally, the TAZ-TEAD2 pathway drives HCC growth via ANLN and KIF23, and crosstalk with mevalonate metabolism may exist. Therefore, modulating farnesyl diphosphate kinase activity could be a therapeutic strategy in HCC.
Statin-associated neuromyotoxicity
Statins, which inhibit HMG-CoA reductase and deplete mevalonate pathway intermediates including FPP, can cause muscle and nerve toxicity. Although the exact mechanisms are not fully understood, reduced FPP availability may impair protein prenylation and ubiquinone synthesis, leading to mitochondrial dysfunction and myopathy. Farnesyl diphosphate kinase activity, by consuming FPP, could exacerbate or modulate this toxicity. Research into this activity may help explain interindividual variability in statin side effects.
Pulmonary arterial hypertension (PAH)
Farnesyl diphosphate synthase (FDPS) regulates endothelial proliferation and autophagy in a rat model of monocrotaline-induced PAH. Since FDPS produces FPP, the substrate for farnesyl diphosphate kinase, altered FPP metabolism may contribute to PAH pathogenesis. Targeting FDPS or downstream enzymes could offer therapeutic benefit, and the kinase activity may represent an additional node for intervention.
Mevalonate kinase deficiency and rare metabolic disorders
Mevalonate kinase (MVK) is an upstream enzyme in the mevalonate pathway, and its inhibition by allosteric FDPS inhibitors has been studied. Deficiencies in MVK cause mevalonate kinase deficiency, a rare autoinflammatory disorder. Farnesyl diphosphate kinase activity acts downstream of MVK, and its dysfunction could theoretically contribute to related metabolic imbalances. However, direct evidence linking this kinase to human disease is currently lacking, and further research is needed.
From farnesyl diphosphate kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of FDPS affect FPP levels and farnesyl diphosphate kinase activity? | CRISPR knockout of FDPS in HepG2 cells |
| Does a point mutation in the ATP-binding site of the kinase abolish activity? | Point mutation knock-in in HEK293 cells |
| Can farnesyl triphosphate be detected in live cells? | Knock-in of a tagged kinase with mass spectrometry |
| Does overexpression of FDFT1 alter FPP flux and HCC growth? | Overexpression of FDFT1 in HCC cell lines |
| Does FDPS inhibition affect autophagy in PAH? | Knockout of FDPS in rat pulmonary endothelial cells |
| Does farnesyl diphosphate kinase activity influence Ras prenylation? | Knockout of the kinase in Ras-transformed cells |
How to Study the farnesyl diphosphate kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioactive kinase assay | Enzymatic conversion of FPP to farnesyl triphosphate | Kinetic characterization of purified enzyme |
| LC-MS/MS | Levels of FPP, farnesyl triphosphate, and other isoprenoids | Metabolic flux analysis in cells |
| CRISPR knockout screen | Genes affecting cell fitness under pathway inhibition | Identifying synthetic lethal targets |
| Immunoblotting | Protein prenylation status | Assessing Ras farnesylation |
| Click chemistry | Incorporation of azido-farnesyl into proteins | Visualizing prenylated proteins |
| RNA-seq | Transcriptional changes in mevalonate pathway genes | Evaluating SREBP target gene expression |
| Autophagy flux assay | LC3-II levels and autophagic flux | Studying FDPS regulation in PAH |
| Cell proliferation assay | Growth rate of cancer cells | Testing FDFT1 or FDPS knockout effects |
Enzymatic assays for kinase activity
Direct measurement of farnesyl diphosphate kinase activity can be performed using radioactive ATP (e.g., [gamma-32P]ATP) and FPP as substrates, followed by thin-layer chromatography or HPLC to separate farnesyl triphosphate from ATP and ADP. Alternatively, coupled enzyme assays that detect ADP production (e.g., pyruvate kinase/lactate dehydrogenase) can be used. These methods require purified enzyme or cell lysates and are suitable for kinetic studies and inhibitor screening.
Metabolic flux analysis with stable isotopes
Stable isotope labeling (e.g., 13C-acetate or 13C-mevalonate) combined with mass spectrometry can trace the flux of carbon through the mevalonate pathway, including FPP and its derivatives. This approach can reveal how genetic perturbations (e.g., FDPS knockout) affect FPP pools and downstream products like cholesterol and farnesyl triphosphate. It is particularly useful for studying the interplay between farnesyl diphosphate kinase activity and other branches of the pathway.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens can identify genes that modulate sensitivity to mevalonate pathway inhibitors or that regulate FPP levels. For example, screens in HCC cell lines treated with FDFT1 inhibitors could reveal synthetic lethal interactions with farnesyl diphosphate kinase. Such screens require robust libraries and bioinformatics pipelines to analyze sgRNA enrichment.
Proteomics and prenylation analysis
Protein prenylation status can be assessed by immunoblotting with anti-farnesyl antibodies or by click chemistry using azido-farnesyl analogs. Changes in farnesyl diphosphate kinase activity may alter the pool of FPP available for prenylation, which can be monitored in cells with genetic modifications. Mass spectrometry-based proteomics can also identify prenylated proteins and quantify their modification state.
How CRISPR Can Be Used to Study GO:0047887 farnesyl diphosphate kinase activity
Knockout
CRISPR knockout of genes involved in FPP metabolism, such as FDPS or FDFT1, can be used to study the consequences of reduced substrate availability for farnesyl diphosphate kinase activity. For example, FDPS knockout in pulmonary endothelial cells reduces FPP and affects proliferation and autophagy. In HCC cells, FDFT1 knockout decreases cholesterol and bile acid production and delays tumor progression. These models help establish causal links between the pathway and disease phenotypes.
Point Mutation
Point mutations can be introduced into the catalytic domain of the putative farnesyl diphosphate kinase or into upstream enzymes like MVK to dissect specific residues required for activity. For instance, mutations in the ATP-binding pocket can abolish kinase activity while preserving substrate binding, allowing separation of catalytic and non-catalytic functions. Such models are valuable for understanding the enzyme's mechanism and for validating inhibitor specificity.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins into the endogenous locus of the kinase or related genes enables visualization and purification of the enzyme complex. Tagged knock-in models can be used for co-immunoprecipitation to identify interacting proteins, or for live-cell imaging to track localization. Additionally, knock-in of disease-associated mutations (e.g., in MVK) can model rare metabolic disorders.
Overexpression
Overexpression of FDPS, FDFT1, or the kinase itself can increase flux through the mevalonate pathway and elevate FPP levels, potentially enhancing farnesyl diphosphate kinase activity. This approach is useful for gain-of-function studies, such as testing whether increased FPP drives cell proliferation or cholesterol synthesis. Overexpression models can also be used to screen for inhibitors that target the kinase or upstream enzymes.
How EDITGENE Supports farnesyl diphosphate kinase activity Research
Researchers studying farnesyl diphosphate kinase activity-related genes often need to determine whether a candidate gene is causally involved in FPP metabolism, isoprenoid biosynthesis, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations, from gene knockout to precise point mutations and knock-in of reporter tags. By leveraging these tools, scientists can dissect the molecular mechanisms of GO:0047887 and its role in cancer, metabolic disorders, and cardiovascular disease.
Contact EDITGENE today to design your custom CRISPR model for farnesyl diphosphate kinase activity research.
Frequently Asked Questions About farnesyl diphosphate kinase activity
What is farnesyl diphosphate kinase activity?
Farnesyl diphosphate kinase activity (GO:0047887) is a molecular function that catalyzes the phosphorylation of 2-trans,6-trans-farnesyl diphosphate (FPP) to farnesyl triphosphate using ATP, producing ADP.
What genes are involved in farnesyl diphosphate kinase activity?
Genes involved in the mevalonate pathway that produce or consume FPP, such as FDPS, FDFT1, MVK, and HMGCR, are closely related to this activity.
What is the reaction catalyzed by farnesyl diphosphate kinase?
The reaction is: 2-trans,6-trans-farnesyl diphosphate + ATP = 2-trans,6-trans-farnesyl triphosphate + ADP.
How is farnesyl diphosphate kinase activity regulated?
It is primarily regulated by substrate availability (FPP and ATP), which is controlled by upstream enzymes like FDPS and MVK, and by statins that inhibit HMG-CoA reductase.
What diseases are associated with farnesyl diphosphate kinase activity?
Dysregulation of FPP metabolism is linked to hepatocellular carcinoma, statin-associated neuromyotoxicity, and pulmonary arterial hypertension.
What are the synonyms for farnesyl diphosphate kinase activity?
Synonyms include ATP:farnesyl-diphosphate phosphotransferase activity, farnesyl-diphosphate kinase activity, and farnesyl pyrophosphate kinase activity.
How can I study farnesyl diphosphate kinase activity in the lab?
You can use radioactive kinase assays, LC-MS/MS for isoprenoid quantification, CRISPR knockout of pathway genes, and prenylation analysis by immunoblotting.
What cell models are available for farnesyl diphosphate kinase research?
Common models include HepG2 and Huh7 for liver cancer, HEK293 for biochemical assays, and primary endothelial cells for pulmonary hypertension studies.
Is farnesyl diphosphate kinase a drug target?
Inhibitors of upstream enzymes like FDPS and farnesyltransferase are under investigation, and modulating this kinase activity could indirectly affect FPP flux and prenylation.
What is the difference between farnesyl diphosphate kinase and farnesyl diphosphate synthase?
Farnesyl diphosphate synthase (FDPS) produces FPP, while farnesyl diphosphate kinase (GO:0047887) phosphorylates FPP to farnesyl triphosphate.
Conclusion
Farnesyl diphosphate kinase activity (GO:0047887) represents a specific enzymatic step in the mevalonate pathway that converts FPP to farnesyl triphosphate. Although the human enzyme remains to be fully characterized, its substrate FPP is a critical node for cholesterol synthesis, protein prenylation, and cellular signaling. Dysregulation of this pathway is implicated in hepatocellular carcinoma, statin-associated neuromyotoxicity, and pulmonary arterial hypertension. By using CRISPR-based knockout, point mutation, knock-in, and overexpression models, researchers can dissect the role of this activity in health and disease. EDITGENE offers comprehensive services to accelerate such studies, from custom cell line generation to library screening and bioinformatics analysis.
References
- 1. Cai D et al.. 2025. Targeting FDFT1 Reduces Cholesterol and Bile Acid Production and Delays Hepatocellular Carcinoma Progression Through the HNF4A/ALDOB/AKT1 Axis.. Adv Sci (Weinh) 12(12):e2411719 PMID: 39899681
- 2. Saito Y et al.. 2023. A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23.. Gastroenterology 164(7):1279-1292 PMID: 36894036
- 3. Baker SK et al.. 2005. Statin-associated neuromyotoxicity.. Drugs Today (Barc) 41(4):267-93 PMID: 16034491
- 4. Salari S et al.. 2024. Inhibition of human mevalonate kinase by allosteric inhibitors of farnesyl pyrophosphate synthase.. FEBS Open Bio 14(8):1320-1339 PMID: 38923323
- 5. Krisans SK et al.. 1994. Farnesyl-diphosphate synthase is localized in peroxisomes.. J Biol Chem 269(19):14165-9 PMID: 8188698
- 6. Baker SK et al.. 2005. Statin-associated neuromyotoxicity.. Timely Top Med Cardiovasc Dis 9:E26 PMID: 16215630
- 7. Patel DV et al.. 1995. Farnesyl diphosphate-based inhibitors of Ras farnesyl protein transferase.. J Med Chem 38(15):2906-21 PMID: 7636851
- 8. Jin T et al.. 2022. Farnesyl diphosphate synthase regulated endothelial proliferation and autophagy during rat pulmonary arterial hypertension induced by monocrotaline.. Mol Med 28(1):94 PMID: 35962329
